<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Retinitis pigmentosa: Clinical presentation and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Retinitis pigmentosa: Clinical presentation and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Retinitis pigmentosa: Clinical presentation and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seema Garg, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew F Gardiner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Retinitis pigmentosa (RP) comprises a complex group of inherited dystrophies characterized by progressive degeneration and dysfunction of the retina, primarily affecting photoreceptor and retinal pigment epithelial function [<a href="#rid1">1</a>]. The retinal pigment epithelium (RPE) is the layer of the retina below the photoreceptors that plays a key role in the maintenance of the photoreceptor layer. RP may occur alone or as part of a syndrome and may be inherited as a dominant, recessive, or X-linked trait or occur sporadically. The same genetic mutation may cause different symptoms in different individuals, and the same syndrome may be caused by different mutations [<a href="#rid2">2</a>].</p><p>Night and peripheral vision are lost progressively, leading to a constricted visual field and markedly diminished vision in some patients. Retinal degeneration can be seen on ophthalmoscopy as typical bone-spicule deposits or attenuated retinal vessels, or detected in early stages by special tests of retinal function.</p><p>This topic addresses the natural history, diagnosis, and genetics of RP. Treatment and prognosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6911.html" rel="external">"Retinitis pigmentosa: Treatment"</a>.)</p><p class="headingAnchor" id="H1378811648"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The term "retinitis" is a misnomer since the pathogenesis is not inflammatory; rather, it is actually a dystrophy or genetically determined degeneration. The term “pigmentosa” refers to the characteristic progressive peripheral pigmentary changes that are seen on fundoscopic examination of the retina. This fundus appearance is thought to be due to two types of pigmented cells that invade the retina in response to photoreceptor damage: retinal pigment epithelium (RPE) cells that migrate away from the retinal pigment epithelial layer, and macrophage-like cells that contain melanin. Other terms for RP include "rod-cone dystrophy," "tapetoretinal degeneration," and "pigmentary retinopathy."</p><p class="headingAnchor" id="H2439862265"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>A family history of RP is present in about 40 to 50 percent of patients [<a href="#rid3">3</a>]. The worldwide prevalence of RP is estimated at 1 in 4000 to 5000 [<a href="#rid4">4-8</a>]. With a population of about 330 million in the United States in February 2021 (see <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.census.gov%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLOlR3S4Jceo7vks10wIe5z8%3D&amp;TOPIC_ID=6905" target="_blank">census.gov</a> for continuous updates), about 82,500 to 110,000 people in the United States have RP or a related disorder. RP may be higher in isolated populations with a high rate of consanguinity.</p><p class="headingAnchor" id="H1036385340"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>The presentation of retinitis pigmentosa (RP) is variable, affecting some patients with visual loss in childhood while leaving others asymptomatic well into adulthood. The typical course of RP is gradual loss of peripheral visual fields (often recognized by testing before an affected individual notices symptoms), visual acuity, and electroretinographic activity. Central retinal function declines more slowly than more peripheral retinal function [<a href="#rid9">9,10</a>]. Most patients meet criteria for legal blindness by age 40 due to narrowing of visual fields [<a href="#rid8">8</a>].</p><p>The rate of loss may be highly variable, depending on the specific mutation. Often times the peripheral vision loss is insidious, and patients may not realize it until they have trouble going down the stairs (inferior visual field), become surprised by someone walking beside them, or get into a car accident due to not seeing vehicles in adjacent lanes.</p><p>In two longitudinal studies of patients with RP, followed for three and nine years, the visual field diminished at a rate of 4.6 to 12 percent per year [<a href="#rid9">9,10</a>]. Three distinct patterns of visual field loss were identified in another longitudinal study: progressive, generalized constriction; expansion from a midperipheral ring scotoma; or loss beginning superiorly and expanding nasally or temporally [<a href="#rid11">11</a>].</p><p>Visual acuity declines more slowly than loss of visual fields [<a href="#rid9">9,10</a>]. The presence of macular lesions on initial presentation is associated with greater loss of visual acuity [<a href="#rid12">12</a>]. Patients with a normal macula lost on average one line of visual acuity over five years, while patients with a macular lesion lost an average of three to four lines over five years.</p><p>Measurement of cone electroretinograms may help estimate the long-term visual prognosis for a given patient, and serial measurements can help refine this prediction [<a href="#rid13">13</a>] (see <a class="local">'Full-field electroretinography'</a> below). In one report, patients at age 40 with a cone amplitude ≥3.5 microV (an estimated 25 percent of patients with typical RP) would on average be expected to retain some vision throughout their lifespan without treatment [<a href="#rid13">13</a>].</p><p>The age of symptom onset, ranging from childhood to adulthood, does not correlate well with the onset of photoreceptor degeneration [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H2550029578"><span class="h1">GENETICS</span></p><p class="headingAnchor" id="H4162249738"><span class="h2">Inheritance</span><span class="headingEndMark"> — </span>There are multiple patterns of inheritance, and underlying gene abnormalities, for disorders classified as retinitis pigmentosa (RP). The same genetic mutation may cause different phenotypic patterns in different patients (phenotypic pleiotropy), and multiple genetic abnormalities may give rise to the same syndrome (allelic heterogeneity). A list of identified genes causing RP is available at the Retinal Information Network (RetNet) website [<a href="#rid15">15</a>].</p><p>Determining the specific genetic abnormality underlying RP can serve several functions:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm the diagnosis of RP in equivocal cases</p><p class="bulletIndent1"><span class="glyph">●</span>Predict prognosis for patient and risk for other family members</p><p class="bulletIndent1"><span class="glyph">●</span>Identify types of RP for clinical trial eligibility as gene-specific prevention and treatment protocols become available</p><p></p><p>Additionally, identifying the cause of the disease will contribute to a better understanding of the biology of the retina and its pathology.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-syndromic RP</strong> – The typical form of RP, in which clinical manifestations are restricted to the eye. This comprises approximately 65 percent of all cases in the United States [<a href="#rid2">2</a>]. The distribution of inheritance patterns for these cases is approximately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>30 percent autosomal dominant</p><p class="bulletIndent2"><span class="glyph">•</span>20 percent autosomal recessive</p><p class="bulletIndent2"><span class="glyph">•</span>15 percent X-linked</p><p class="bulletIndent2"><span class="glyph">•</span>5 percent recessive early-onset (Leber congenital amaurosis [LCA])</p><p class="bulletIndent2"><span class="glyph">•</span>30 percent sporadic</p><p></p><p class="bulletIndent1">Autosomal dominant RP confers a 50 percent risk to the offspring of affected individuals. In autosomal recessive RP, each child has a 25 percent risk of being affected if both parents are carriers. X-linked RP patients are typically male. However, female carriers of X-linked RP may have visual symptoms [<a href="#rid16">16</a>]. Affected males cannot transmit the abnormal gene to their male offspring, but all female offspring will be carriers. Where there is no family history of RP and an abnormal gene cannot be determined, the risk of RP affecting offspring is less than 5 percent unless the proposed union is consanguineous [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic RP</strong> – In addition to typical forms of RP, syndromic forms exist that involve multiple organs. The most common form of syndromic RP is Usher syndrome. Usher patients have congenital or early-onset hearing impairment followed by development of RP. Bardet-Biedl syndrome is the next most common syndromic form and is associated with polydactyly, obesity, renal abnormalities, and developmental delay. Mutations involving the nephronophthisis (NPHP) genes are well characterized and cause childhood end-stage kidney disease and RP. (See  <a class="medical medical_review" href="/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis"</a>.)</p><p></p><p class="headingAnchor" id="H1965993949"><span class="h2">Gene mutations</span><span class="headingEndMark"> — </span>Linkage analyses in families with multiple affected individuals have resulted in the identification of numerous genomic regions that harbor mutations causing RP. The first RP mutation was identified in 1989 in the rhodopsin gene (<em>RHO</em>) on chromosome 3q21.3 [<a href="#rid17">17</a>]. Rhodopsin is a light-absorbing pigment in the membrane of the rod photoreceptor cell. A proline-to-histidine change at amino acid 23 in this gene was found in 1990 [<a href="#rid18">18</a>]. This mutation alone accounts for 10 percent of autosomal dominant RP in the United States White population.</p><p>The pace of discovery has been exponential, as more than 3000 genetic mutations in approximately 70 genes have been discovered [<a href="#rid19">19</a>]. Over 71 genes have been implicated in non-syndromic RP, 66 genes in syndromic RP, and 14 genes in LCA [<a href="#rid15">15</a>]. The protein products of these genes are involved in multiple pathways: the phototransduction cascade; vitamin A metabolism; cytoskeletal structures; signaling and cell-to cell-interactions; RNA intron splicing factors; regulation of intracellular protein traffic; and phagocytosis. RetNet provides information on advancements in gene mutations [<a href="#rid15">15</a>].</p><p>It is possible to detect disease-causing mutations in over 50 percent of patients with autosomal dominant RP, 30 percent of patients with recessive RP, 70 percent of patients with recessive LCA, and nearly 90 percent of patients with X-linked RP [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1838498004"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>The visual symptoms of retinitis pigmentosa (RP) arise primarily from the loss of retinal photoreceptors, both rods and cones. The most common symptoms are night blindness, peripheral visual field loss, and loss of visual acuity. Other symptoms commonly reported by patients with RP include photopsias (sensations of sparkling lights) [<a href="#rid4">4,21</a>] and headache [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Night blindness</strong> – Night blindness (nyctalopia) is one of the earliest symptoms [<a href="#rid4">4-8</a>]. Patients may notice that they become disoriented in dim light or that adaptation to dim light is slow, as in movie theaters. However, night blindness may go unrecognized until the disease is advanced due to the insidious nature of RP and pervasive artificial light sources which are now present in everyday life; some patients never recognize night blindness as a symptom [<a href="#rid21">21</a>]. Once a patient is suspected of having RP, they should be referred to an ophthalmologist who specializes in hereditary eye disease or to a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nsgc.org%2F&amp;token=OJpa7WnHcNTDFJJhmVS3w6cJAXco8VpFrKoDhZ0I150%3D&amp;TOPIC_ID=6905" target="_blank">genetics professional</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual field loss</strong> – Progressive constriction of the visual field is another common feature. Patients may be considered "clumsy" before the diagnosis is made [<a href="#rid7">7</a>]. The most common early pattern of visual field deficit is loss in the midperiphery of the visual field (between 30 to 50 degrees eccentric to fixation, as this is where the density of rods is greatest), followed by extension of the visual loss into the far periphery of the visual field [<a href="#rid4">4</a>]. Patients may experience no impact from a decrement in visual field until the central visual field is reduced to about 50 degrees in diameter (normal is 180 degrees with both eyes open) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual acuity</strong> – Visual acuity is variably affected. Patients may retain good visual acuity for years, despite extensive loss of peripheral vision. Eventually, most patients experience loss of visual acuity as the disease progression. In a study of 982 adult patients with RP, 52 percent had visual acuity of 20/40 or better in at least one eye and 25 percent had visual acuity of 20/200 or worse in both eyes. Only 5 percent had no light perception in both eyes. Patients with X-linked RP tend to have poorest visual acuity; those with autosomal dominant RP typically retain better visual acuity [<a href="#rid9">9,22,23</a>].</p><p></p><p>Cataracts and abnormalities in the central retina, such as macular edema or macular cysts, often contribute to deterioration in visual acuity [<a href="#rid22">22,24,25</a>].</p><p>The functional impact of RP, in terms of difficulty with activities of daily living, correlates most strongly with loss of visual acuity [<a href="#rid26">26</a>]. Loss of visual field has less impact, and decrements detected by electroretinographic data correlate least well with activity impairment. (See <a class="local">'Full-field electroretinography'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Ocular findings</span></p><p class="headingAnchor" id="H7"><span class="h3">Retina</span><span class="headingEndMark"> — </span>The classic ophthalmoscopic findings in retinitis pigmentosa (RP) are described as a triad: attenuation of the retinal blood vessels, waxy pallor of the optic disc, and intraretinal pigmentation in a bone-spicule pattern (<a class="graphic graphic_picture graphicRef81281" href="/d/graphic/81281.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef53849" href="/d/graphic/53849.html" rel="external">picture 2</a>). These retinal findings are most often bilateral and symmetric. Unilateral RP is rare. Retinal vascular attenuation was found in 94 percent of 384 eyes and optic disc pallor in 52 percent in one series [<a href="#rid27">27</a>].</p><p>The optic disc has a waxy, pale appearance thought to be due to both optic disc atrophy and gliosis overlying the disc [<a href="#rid4">4,5,7</a>]. Drusen of the optic disc (hyaline-like, acellular, laminated globular excrescences) are due to aberrant axonal transport and are more common in patients with RP than in the general population [<a href="#rid28">28,29</a>].</p><p>The retina may appear normal in early states of RP, even though electrophysiologic testing reveals dysfunction of the photoreceptors (see <a class="local">'Full-field electroretinography'</a> below). This "early" stage may last for decades [<a href="#rid4">4</a>]. As the disease advances, the retinal vessels become more attenuated until they appear thread-like.</p><p>Abnormal retinal pigmentation develops when pigment migrates from disintegrating retinal pigment epithelial cells into the superficial ("inner") retina in response to photoreceptor cell death (<a class="graphic graphic_figure graphicRef67585" href="/d/graphic/67585.html" rel="external">figure 1</a>) [<a href="#rid4">4,7</a>]. The pigmentary abnormality is visible initially as a dusting of fine pigment extending from the mid to far peripheral retina. Later, "bone spicules" (accumulations of pigment along the interstitial spaces surrounding retinal blood vessels) form throughout the mid and far retinal periphery [<a href="#rid30">30</a>]. Atrophy of the choriocapillaris may be present in advanced RP, exposing the large choroidal vessels underneath [<a href="#rid4">4,7</a>].</p><p>The macula, or central retina, becomes affected in moderate or advanced disease, when photoreceptor degeneration advances and leads to retinal thinning and loss of visual acuity [<a href="#rid7">7,24,27,31</a>]. A central atrophic or bulls-eye lesion will be visible in some patients [<a href="#rid4">4,27</a>].</p><p>Patients may also develop cellophane maculopathy (also called "surface wrinkling retinopathy") and foveal cysts, with or without associated edema [<a href="#rid24">24,25,27</a>]. These problems compound the loss of visual acuity due to photoreceptor death.</p><p class="headingAnchor" id="H9"><span class="h3">Lens</span><span class="headingEndMark"> — </span>Cataracts, especially posterior subcapsular cataracts, affect approximately 50 percent of patients with RP [<a href="#rid4">4,5,7,27,32</a>]. Cataract prevalence is higher in the autosomal dominant subtype [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Vitreous</span><span class="headingEndMark"> — </span>The vitreous humor may contain a dust-like pigmented substance, comprised of pigment granules [<a href="#rid21">21</a>]. Complete posterior vitreous detachment is more common than in normal subjects [<a href="#rid4">4,5,7,8,27,33</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Functional abnormalities</span><span class="headingEndMark"> — </span>Abnormalities in refractive error, visual acuity and visual fields, contrast sensitivity, and color vision may occur in patients with RP.</p><p class="headingAnchor" id="H12"><span class="h3">Refractive error</span><span class="headingEndMark"> — </span>RP is associated with astigmatism and myopia [<a href="#rid4">4,7,34</a>]. In one study, myopia was present in 75 percent of 268 eyes of patients with RP and in only 12 percent of a normal population [<a href="#rid34">34</a>]. The prevalence of myopia is higher in patients with X-linked RP. (See  <a class="medical medical_review" href="/d/html/6895.html" rel="external">"Visual impairment in adults: Refractive disorders and presbyopia"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Visual acuity and visual fields</span><span class="headingEndMark"> — </span>Visual loss in RP usually begins with mid-peripheral scotomata that progress over time to involve the entire periphery. Loss of photoreceptors in the macula in advanced disease leads to progressive constriction of the central visual field and worsening visual acuity. Patients are left with a central island of vision that gradually constricts over time.</p><p class="headingAnchor" id="H14"><span class="h3">Contrast sensitivity</span><span class="headingEndMark"> — </span>Standard visual acuity is measured at high contrast. The ability to distinguish low-contrast objects is another measure of visual function that is diminished in patients with RP [<a href="#rid35">35</a>]. Loss of contrast sensitivity may contribute to patients' perception of decreased vision when standard visual acuity testing is normal.</p><p class="headingAnchor" id="H15"><span class="h3">Color vision</span><span class="headingEndMark"> — </span>Color vision remains normal until the macula becomes involved and visual acuity is reduced. When color vision is affected, testing usually reveals a blue cone deficiency [<a href="#rid4">4,6,8</a>].</p><p class="headingAnchor" id="H16"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of retinosis pigmentosa (RP) is made by a combination of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>History (nyctalopia [difficulty adapting to the dark] and peripheral vision loss)</p><p class="bulletIndent1"><span class="glyph">●</span>Fundus examination findings of waxy pallor of the optic nerve, arterial attenuation, and pigmentary changes in the peripheral retina</p><p class="bulletIndent1"><span class="glyph">●</span>Ancillary testing results (attenuation of the rods, and later cones, on the full-field electroretinogram [ERG], constriction of the visual field on Goldmann perimetry, and abnormal dark adaptometry)</p><p></p><p>In normal subjects undergoing ERG testing in a dark environment, there is an initial increase in sensitivity to low light, a phenomenon mediated by cone photoreceptors that reaches a plateau within five minutes. Subsequently, the rod system progressively activates and sensitivity to light increases again until a second plateau is reached. Abnormalities of dark adaptometry in RP include loss of rod and/or cone sensitivity [<a href="#rid4">4,6,7,36</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Full-field electroretinography</span><span class="headingEndMark"> — </span>The ERG, a mainstay in the diagnosis of RP since the early 1950s, measures the electrical response of the retina to light stimuli [<a href="#rid37">37</a>]. Full-field electroretinography, the traditional standard, activates the entire retina simultaneously. An electrode is placed on the cornea or on the skin of the eyelid and the color and intensity of a light stimulus are manipulated to activate the cones and rods, separately or together.</p><p>RP causes a reduction in the amplitude and a delay in the timing of the electrical signal produced by retinal stimulation [<a href="#rid38">38</a>]. The amplitude of the ERG correlates well with the size of the remaining visual field [<a href="#rid39">39</a>]. Patients with moderate or advanced RP have a non-recordable (extinguished) ERG.</p><p>The ERG may be abnormal even in early stages of the disease, when the retina appears normal. Full-field electroretinography is invaluable in detecting RP in patients at risk for the disease (eg, family members of diagnosed patients) who have normal-appearing retinas.</p><p class="headingAnchor" id="H1231810384"><span class="h2">Goldman perimetry</span><span class="headingEndMark"> — </span>Goldmann perimetry involves moving a stimulus from beyond the edge of the visual field into the field. The location at which the stimulus is first seen marks the outer perimeter of the visual field for the size and brightness of the stimulus tested. The largest isopter in Goldmann testing extends 90 degrees temporally and 60 degrees in other quadrants. This test is conducted one eye at a time to determine the extent of visual field loss and to follow the patient’s visual field progression over time.</p><p class="headingAnchor" id="H1512647742"><span class="h2">Dark adaptometry</span><span class="headingEndMark"> — </span>An abnormal dark-adapted threshold, a psychophysical measurement of the threshold to a light stimulus, is a hallmark feature of RP. Rod threshold is often increased due to decreased rod sensitivity and prolonged recovery of rod sensitivity. After being exposed to a bright light stimulus, subjects are placed in the dark for 30 minutes, and the minimum intensity light that can be detected by the subject is measured at interval time points.</p><p class="headingAnchor" id="H19"><span class="h2">Multifocal electroretinography for monitoring</span><span class="headingEndMark"> — </span>Focal electroretinography records the local electrical signal generated by the stimulation of a discrete portion of the retina. Multifocal electroretinography, another technique, permits the recording of many focal electroretinograms simultaneously and represents central cone function [<a href="#rid40">40</a>].</p><p>The multifocal ERG is useful in monitoring patients with RP in later stages of the disease. This technique can record electroretinographic responses generated within the functioning maculae in patients who have nearly extinguished full-field ERGs [<a href="#rid41">41-43</a>].</p><p class="headingAnchor" id="H197286973"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>With the first retinal gene therapy (voretigene neparvovec-rzyl) approved by the US Food and Drug Administration (FDA) in December 2017 for RPE65-associated Leber congenital amaurosis (LCA) and a multitude of ongoing gene therapy trials, genetic testing has become a critical component in the diagnosis and management of RP. Gene therapy is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6911.html" rel="external">"Retinitis pigmentosa: Treatment"</a> and  <a class="medical medical_review" href="/d/html/6911.html" rel="external">"Retinitis pigmentosa: Treatment", section on 'Gene therapy'</a>.)</p><p>In 2006, the National Eye Institute sponsored eyeGENE, a program which provided genetic testing for patients with a variety of inherited eye diseases [<a href="#rid44">44</a>]. In 2016, the American Academy of Ophthalmology released a position statement on the role of genetic testing in inherited retinal disease management [<a href="#rid20">20</a>]. As treatment is available for a subtype of LCA/RP, it is essential that genetic testing be offered for patients with LCA and early-onset RP. In addition, a molecular diagnosis obtained from genetic testing allows patients to determine whether they are eligible for inclusion into clinical trials for RP.</p><p>Certification under the Clinical Laboratory Improvements Amendment (CLIA) is essential for clinical genetic testing in the United States. In addition, the genetic analysis provided by the laboratory should follow American College of Medical Genetics and Genomics standards. Skilled interpretation of the pathogenicity of identified variants (mutations) is important to sort out the clinical relevance of the results of genetic testing.</p><p>Several commercial ocular genetics laboratories offer large, comprehensive, next-generation sequencing retinal dystrophy panels with rapid turnaround of results. Nonprofit laboratories, such as the John and Marcia Carver Nonprofit Genetic Testing Laboratory at the University of Iowa, and Massachusetts Eye and Ear, also offer comprehensive testing.</p><p>The Foundation Fighting Blindness (FFB) is offering genetic testing and ocular genetic counseling as part of a research study available through the free online <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.myretinatracker.org%2F&amp;token=cRsqfKOP3qZXnSR6sI35rPwx%2Fl3BGiK9iWtVTtDwdjln%2Fip4XSltR6Jv3XhydZ6d&amp;TOPIC_ID=6905" target="_blank">My Retina Tracker registry</a>. Patients in the My Retina Tracker registry provide informed consent to share their deidentified data, which is accessible to researchers to help accelerate progress on RP and other inherited retinal diseases research. It is essential that a patient that has undergone genetic testing be referred for ocular genetic counseling, which can be provided by a geneticist or a certified genetic counselor.</p><p class="headingAnchor" id="H20"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several acquired conditions cause extensive chorioretinopathy and may be confused with retinitis pigmentosa (RP). These include traumatic retinopathy, retinal inflammatory diseases, paraneoplastic retinopathy, drug toxicity, and rare conditions such as diffuse unilateral subacute neuroretinitis (DUSN).</p><p class="headingAnchor" id="H21"><span class="h2">Traumatic retinopathy</span><span class="headingEndMark"> — </span>Traumatic retinopathy is the most common masquerader of RP [<a href="#rid45">45</a>]. Several months after blunt or penetrating injury to the eye, the retina may assume an appearance similar to that of RP (however, trauma is often unilateral and RP is almost always bilateral) [<a href="#rid46">46</a>]. The retinal pigment epithelium (RPE) becomes atrophic and dark retinal pigment migrates into the superficial retina, especially along retinal vessels. This bone-spicule pattern is sometimes indistinguishable from that seen in RP. These changes do result in visual loss, but, in contrast to RP, the loss is not progressive over time and the electroretinogram (ERG) may even be normal.</p><p class="headingAnchor" id="H22"><span class="h2">Retinal inflammatory diseases</span><span class="headingEndMark"> — </span>Pigmentary retinopathies may occur in rubella, syphilis, toxoplasmosis, and herpesvirus infection of the retina. Rubella retinopathy is the most common ocular manifestation of congenital rubella [<a href="#rid47">47</a>]. If a child has congenital hearing loss secondary to rubella infection and concurrent rubella retinopathy, the child may be mistakenly diagnosed with Usher syndrome, a genetic disorder affecting the cochlea and retina (see <a class="local">'Genetics'</a> above). Electroretinography may facilitate the correct diagnosis, as the ERG is only mildly abnormal in rubella but severely abnormal in Usher syndrome.</p><p>Congenital or acquired syphilis may mimic advanced RP [<a href="#rid48">48</a>]. However, unlike RP, syphilis produces patchy pigmentary retinal changes and chorioretinal scars.</p><p>Toxoplasmosis or herpes infections of the retina may also produce a pigmentary retinopathy. Random patches of severe retinopathy occur with these infections, similar to syphilis retinopathy. The ERG is usually only mildly abnormal in inflammatory pigmentary retinopathies but markedly abnormal in RP.</p><p class="headingAnchor" id="H23"><span class="h2">Autoimmune paraneoplastic retinopathy</span><span class="headingEndMark"> — </span>Although rare, panretinal degeneration can accompany certain cancers, particularly small-cell lung and cervical carcinoma. The ERG is usually severely abnormal. Cancer-associated retinopathy (CAR) is thought to be due to antiretinal autoantibodies [<a href="#rid49">49</a>]. Melanoma-associated retinopathy (MAR) presents with night blindness but has a unique ERG pattern distinguishable from that of RP. (See  <a class="medical medical_review" href="/d/html/15837.html" rel="external">"Paraneoplastic visual syndromes"</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Drug toxicity</span><span class="headingEndMark"> — </span>Phenothiazines and <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> bind to melanin and concentrate in the RPE. <a class="drug drug_general" data-topicid="9991" href="/d/drug information/9991.html" rel="external">Thioridazine</a> in doses higher than 800 mg/day can cause severe retinal toxicity. This toxicity may manifest as a pigmentary retinopathy that mimics early RP [<a href="#rid50">50</a>].</p><p><a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">Chloroquine</a> retinopathy may develop when total doses exceed 300 g [<a href="#rid51">51</a>]. Bone spicules may develop in the peripheral retina but, unlike with RP, dark adaptometry is usually normal. <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> retinopathy, which is less common than chloroquine retinopathy, may develop after medication use for longer than five years and at a dose of greater than 6.5 mg/kg/day. The retinopathy is typically milder than chloroquine retinopathy.</p><p class="headingAnchor" id="H25"><span class="h2">Diffuse unilateral subacute neuroretinitis</span><span class="headingEndMark"> — </span>DUSN is a rare panretinal degeneration secondary to infection with the worms <em>Baylisascaris procyonis</em> and <em>Toxocara canis</em>. In the late stages, the fundus appearance resembles that of advanced RP, but unlike RP the abnormalities are typically restricted to one eye. (See  <a class="medical medical_review" href="/d/html/5716.html" rel="external">"Toxocariasis: Visceral and ocular larva migrans"</a> and  <a class="medical medical_review" href="/d/html/487.html" rel="external">"Anthelminthic therapies"</a>.)</p><p class="headingAnchor" id="H100085797"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83035.html" rel="external">"Patient education: Retinitis pigmentosa (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Retinitis pigmentosa (RP) comprises a group of inherited conditions that cause progressive retinal degeneration affecting the photoreceptors and retinal pigment epithelium (RPE). A family history is identified in the majority of patients. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – There are multiple patterns of inheritance, and underlying gene abnormalities, for disorders classified as retinitis pigmentosa (RP). The understanding of genetic mutations associated with RP is rapidly expanding.(See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and natural history</strong> – Age of symptom onset ranges from childhood to adulthood, but photoreceptor degeneration can be detected many years before affected individuals are aware of vision problems. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Night blindness is one of the earliest symptoms but can be so gradual that it may go unnoticed by patients. Loss of visual field is progressive, starting in the midperiphery and progressing more peripherally, resulting in a constricted visual field. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular findings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Changes in the ocular fundus seen on ophthalmoscopy include optic disc pallor, attenuated vessels, and pigment deposits in a bone-spicule pattern. The macula may be affected in advanced disease. Cataracts may further compromise central vision. (See <a class="local">'Ocular findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormalities in refractive error, visual acuity and visual fields, contrast sensitivity, and color vision may occur in patients with RP. (See <a class="local">'Functional abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of RP is made by a combination of history (nyctalopia and peripheral vision loss), fundus examination (waxy pallor of the optic nerve, arterial attenuation, and pigmentary changes in the peripheral retina), and ancillary testing results (attenuation of the rods, and later cones, on the full-field electroretinogram [ERG] and constriction of the visual field on Goldmann perimetry). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Acquired conditions resulting in ophthalmoscopic findings resembling RP include ocular trauma, ocular inflammation associated with infection (rubella, syphilis, toxoplasmosis, herpesvirus), paraneoplastic retinopathy, drug toxicity (phenothiazines and <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a>), and diffuse unilateral subacute neuroretinitis (DUSN). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H740372784"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Syndee Givre, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Retinitis pigmentosa. A symposium on terminology and methods of examination. Ophthalmology 1983; 90:126.</a></li><li><a class="nounderline abstract_t">Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol 2007; 125:151.</a></li><li class="breakAll">National Human Genome Research Institute. About retinitis pigmentosa. Available at: https://www.genome.gov/Genetic-Disorders/Retinitis-Pigmentosa (Accessed on August 31, 2022).</li><li class="breakAll">Weleber RG, Gregory-Evans K. Retinitis pigmentosa and allied disorders. In: Retina, Ryan SJ (Ed), Elsevier Mosby, 2006. p.471.</li><li class="breakAll">Berson EL. Retinitis pigmentosa and allied retinal diseases. In: Duane's Clinical Ophthalmology, Tasman W, Jaeger EA (Eds), Lippincott, Williams &amp; Wilkins, 2006.</li><li><a class="nounderline abstract_t">Merin S, Auerbach E. Retinitis pigmentosa. Surv Ophthalmol 1976; 20:303.</a></li><li><a class="nounderline abstract_t">Pagon RA. Retinitis pigmentosa. Surv Ophthalmol 1988; 33:137.</a></li><li><a class="nounderline abstract_t">Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006; 368:1795.</a></li><li><a class="nounderline abstract_t">Berson EL, Sandberg MA, Rosner B, et al. Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol 1985; 99:240.</a></li><li><a class="nounderline abstract_t">Holopigian K, Greenstein V, Seiple W, Carr RE. Rates of change differ among measures of visual function in patients with retinitis pigmentosa. Ophthalmology 1996; 103:398.</a></li><li><a class="nounderline abstract_t">Grover S, Fishman GA, Brown J Jr. Patterns of visual field progression in patients with retinitis pigmentosa. Ophthalmology 1998; 105:1069.</a></li><li><a class="nounderline abstract_t">Flynn MF, Fishman GA, Anderson RJ, Roberts DK. Retrospective longitudinal study of visual acuity change in patients with retinitis pigmentosa. Retina 2001; 21:639.</a></li><li><a class="nounderline abstract_t">Berson EL. Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture. Exp Eye Res 2007; 85:7.</a></li><li><a class="nounderline abstract_t">Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci 1993; 34:1659.</a></li><li class="breakAll">Daiger SP. The University of Texas Heatlh Science Center. RetNet: Retinal Information Network. Available at: https://sph.uth.edu/retnet/ (Accessed on November 07, 2019).</li><li><a class="nounderline abstract_t">Comander J, Weigel-DiFranco C, Sandberg MA, Berson EL. Visual Function in Carriers of X-Linked Retinitis Pigmentosa. Ophthalmology 2015; 122:1899.</a></li><li><a class="nounderline abstract_t">McWilliam P, Farrar GJ, Kenna P, et al. Autosomal dominant retinitis pigmentosa (ADRP): localization of an ADRP gene to the long arm of chromosome 3. Genomics 1989; 5:619.</a></li><li><a class="nounderline abstract_t">Dryja TP, McGee TL, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990; 343:364.</a></li><li><a class="nounderline abstract_t">Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res 2018; 63:107.</a></li><li class="breakAll">American Academy of Ophthalmology. Recommendations on clinical assessment of patients with inherited retinal degenerations - 2016. Available at: https://www.aao.org/clinical-statement/recommendations-on-clinical-assessment-of-patients (Accessed on November 07, 2019).</li><li><a class="nounderline abstract_t">Heckenlively JR, Yoser SL, Friedman LH, Oversier JJ. Clinical findings and common symptoms in retinitis pigmentosa. Am J Ophthalmol 1988; 105:504.</a></li><li><a class="nounderline abstract_t">Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology 1999; 106:1780.</a></li><li><a class="nounderline abstract_t">Berson EL, Rosner B, Simonoff E. Risk factors for genetic typing and detection in retinitis pigmentosa. Am J Ophthalmol 1980; 89:763.</a></li><li><a class="nounderline abstract_t">Fishman GA, Fishman M, Maggiano J. Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol 1977; 95:798.</a></li><li><a class="nounderline abstract_t">Fishman GA, Maggiano JM, Fishman M. Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol 1977; 95:1993.</a></li><li><a class="nounderline abstract_t">Szlyk JP, Fishman GA, Alexander KR, et al. Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa. Arch Ophthalmol 1997; 115:53.</a></li><li><a class="nounderline abstract_t">Pruett RC. Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc 1983; 81:693.</a></li><li><a class="nounderline abstract_t">Novack RL, Foos RY. Drusen of the optic disk in retinitis pigmentosa. Am J Ophthalmol 1987; 103:44.</a></li><li><a class="nounderline abstract_t">Grover S, Fishman GA, Brown J Jr. Frequency of optic disc or parapapillary nerve fiber layer drusen in retinitis pigmentosa. Ophthalmology 1997; 104:295.</a></li><li><a class="nounderline abstract_t">Li ZY, Possin DE, Milam AH. Histopathology of bone spicule pigmentation in retinitis pigmentosa. Ophthalmology 1995; 102:805.</a></li><li><a class="nounderline abstract_t">Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL. The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2005; 46:3349.</a></li><li><a class="nounderline abstract_t">Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol 1982; 93:733.</a></li><li><a class="nounderline abstract_t">Takahashi M, Jalkh A, Hoskins J, et al. Biomicroscopic evaluation and photography of liquefied vitreous in some vitreoretinal disorders. Arch Ophthalmol 1981; 99:1555.</a></li><li><a class="nounderline abstract_t">Sieving PA, Fishman GA. Refractive errors of retinitis pigmentosa patients. Br J Ophthalmol 1978; 62:163.</a></li><li><a class="nounderline abstract_t">Lindberg CR, Fishman GA, Anderson RJ, Vasquez V. Contrast sensitivity in retinitis pigmentosa. Br J Ophthalmol 1981; 65:855.</a></li><li><a class="nounderline abstract_t">GOODMAN G, GUNKEL RD. Familial electroretinographic and adaptometric studies in retinitis pigmentosa. Am J Ophthalmol 1958; 46:142.</a></li><li><a class="nounderline abstract_t">Bjork A, Karpe G. The electroretinogram in retinitis pigmentosa. Acta Ophthalmol Scand 1951; 29:361.</a></li><li><a class="nounderline abstract_t">Berson EL. Retinitis pigmentosa and allied retinal diseases: electrophysiologic findings. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1976; 81:OP659.</a></li><li><a class="nounderline abstract_t">Sandberg MA, Weigel-DiFranco C, Rosner B, Berson EL. The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1996; 37:1693.</a></li><li><a class="nounderline abstract_t">Sutter EE, Tran D. The field topography of ERG components in man--I. The photopic luminance response. Vision Res 1992; 32:433.</a></li><li><a class="nounderline abstract_t">Hood DC, Holopigian K, Greenstein V, et al. Assessment of local retinal function in patients with retinitis pigmentosa using the multi-focal ERG technique. Vision Res 1998; 38:163.</a></li><li><a class="nounderline abstract_t">Seeliger M, Kretschmann U, Apfelstedt-Sylla E, et al. Multifocal electroretinography in retinitis pigmentosa. Am J Ophthalmol 1998; 125:214.</a></li><li><a class="nounderline abstract_t">Gränse L, Ponjavic V, Andréasson S. Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields. Acta Ophthalmol Scand 2004; 82:701.</a></li><li class="breakAll">National Eye Institute. National Ophthalmic Disease Genotyping Network (eyeGENETM). Available at: www.nei.nih.gov.libproxy.lib.unc.edu/resources/eyegene.asp (Accessed on August 01, 2011).</li><li><a class="nounderline abstract_t">Bastek JV, Foos RY, Heckenlively J. Traumatic pigmentary retinopathy. Am J Ophthalmol 1981; 92:621.</a></li><li><a class="nounderline abstract_t">Cogan DG. Pseudoretinitis pigmentosa. Report of two traumatic cases of recent origin. Arch Ophthalmol 1969; 81:45.</a></li><li><a class="nounderline abstract_t">Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. Arch Ophthalmol 1967; 77:434.</a></li><li><a class="nounderline abstract_t">Heckenlively JR. Secondary retinitis pigmentosa (syphilis). Doc Ophthalmol Proc Serv 1977; 13:245.</a></li><li><a class="nounderline abstract_t">Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4:5.</a></li><li><a class="nounderline abstract_t">Hamilton JD. Thioridazine retinopathy within the upper dosage limit. Psychosomatics 1985; 26:823.</a></li><li><a class="nounderline abstract_t">Marks JS. Chloroquine retinopathy: is there a safe daily dose? Ann Rheum Dis 1982; 41:52.</a></li></ol></div><div id="topicVersionRevision">Topic 6905 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6856249" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Retinitis pigmentosa. A symposium on terminology and methods of examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296890" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Perspective on genes and mutations causing retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296890" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Perspective on genes and mutations causing retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296890" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perspective on genes and mutations causing retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296890" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Perspective on genes and mutations causing retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/817406" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3068820" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113430" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3976802" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Natural course of retinitis pigmentosa over a three-year interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600415" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rates of change differ among measures of visual function in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9627658" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Patterns of visual field progression in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756888" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Retrospective longitudinal study of visual acuity change in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531222" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8473105" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Retinitis pigmentosa. The Friedenwald Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8473105" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Retinitis pigmentosa. The Friedenwald Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143542" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Visual Function in Carriers of X-Linked Retinitis Pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2613244" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Autosomal dominant retinitis pigmentosa (ADRP): localization of an ADRP gene to the long arm of chromosome 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137202" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A point mutation of the rhodopsin gene in one form of retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097191" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259404" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical findings and common symptoms in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10485550" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6966889" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk factors for genetic typing and detection in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/860943" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Macular lesions associated with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/921578" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Foveal lesions seen in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006425" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6676982" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Retinitis pigmentosa: clinical observations and correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3799789" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Drusen of the optic disk in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9052635" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Frequency of optic disc or parapapillary nerve fiber layer drusen in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7777280" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Histopathology of bone spicule pigmentation in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123439" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The association between visual acuity and central retinal thickness in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091261" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The frequency of posterior subcapsular cataract in the hereditary retinal degenerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7283804" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Biomicroscopic evaluation and photography of liquefied vitreous in some vitreoretinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/638108" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Refractive errors of retinitis pigmentosa patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7317333" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Contrast sensitivity in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13571366" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Familial electroretinographic and adaptometric studies in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The electroretinogram in retinitis pigmentosa</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/960388" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Retinitis pigmentosa and allied retinal diseases: electrophysiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675413" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1604830" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The field topography of ERG components in man--I. The photopic luminance response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9474387" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of local retinal function in patients with retinitis pigmentosa using the multi-focal ERG technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9467449" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Multifocal electroretinography in retinitis pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606467" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606467" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7304688" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Traumatic pigmentary retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5763219" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pseudoretinitis pigmentosa. Report of two traumatic cases of recent origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4164540" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical manifestations of postnatal and congenital rubella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Secondary retinitis pigmentosa (syphilis)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180904" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4059502" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Thioridazine retinopathy within the upper dosage limit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065730" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chloroquine retinopathy: is there a safe daily dose?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
